Genetic Variants in the 3'UTR of

3’UTR region BRCA1 BRCA2 hereditary breast and ovarian cancer miRNA polymorphism

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
13 May 2020
Historique:
received: 26 02 2020
revised: 01 04 2020
accepted: 10 04 2020
entrez: 17 5 2020
pubmed: 18 5 2020
medline: 18 5 2020
Statut: epublish

Résumé

Hereditary breast and ovarian cancer (HBOC) syndrome is mainly caused by mutations in the

Identifiants

pubmed: 32414209
pii: diagnostics10050298
doi: 10.3390/diagnostics10050298
pmc: PMC7277914
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Universidad Autonoma de Nuevo Leon
ID : Institutional Calls, PAICyT
Organisme : Consejo Nacional de Ciencia y Tecnología (CONACYT)
ID : Posgrade scholarship: 387437

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Mol Cell. 2011 Jan 21;41(2):210-20
pubmed: 21195000
Fam Cancer. 2008;7(1):27-39
pubmed: 17999161
Salud Publica Mex. 2005 Mar-Apr;47(2):110-5
pubmed: 15889636
J Natl Cancer Inst. 2011 Jan 19;103(2):105-16
pubmed: 21169536
Breast Cancer Res Treat. 2011 Feb;125(3):885-91
pubmed: 20848184
Mayo Clin Proc. 2010 Dec;85(12):1111-20
pubmed: 21123638
Asian Pac J Cancer Prev. 2014;15(19):8319-24
pubmed: 25339023
Eur J Hum Genet. 2016 Aug;24(9):1324-9
pubmed: 26785832
JAMA. 1998 Mar 25;279(12):915-21
pubmed: 9544765
Nat Genet. 2006 Jul;38(7):813-8
pubmed: 16751773
J Clin Oncol. 2008 Sep 10;26(26):4282-8
pubmed: 18779615
Immune Netw. 2011 Oct;11(5):227-44
pubmed: 22194706
Hum Mutat. 2012 Dec;33(12):1665-75
pubmed: 22753153
Cell Cycle. 2011 Jan 1;10(1):90-9
pubmed: 21191178
Nat Genet. 2006 Dec;38(12):1452-6
pubmed: 17072316
Med Oncol. 2016 Dec;33(12):135
pubmed: 27807724
Int J Cancer. 2010 Aug 1;127(3):589-97
pubmed: 19950226
Bioinformatics. 2006 Aug 1;22(15):1928-9
pubmed: 16720584
Science. 2002 Sep 13;297(5588):1837-48
pubmed: 12228710
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1362-70
pubmed: 22729394
PLoS One. 2012;7(5):e37432
pubmed: 22655046

Auteurs

María Marisela Sánchez-Chaparro (MM)

Laboratory of Immunology and Virology, Collage of Biological Sciences, Universidad Autónoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon 66451, Mexico.

Idalia Garza-Veloz (I)

Molecular Medicine Laboratory, Human Medicine and HS Academic Unit, Universidad Autonoma de Zacatecas, Zacatecas, Zacatecas 98160, Mexico.

Omar Alejandro Zayas-Villanueva (OA)

University Center Against Cancer (CUCC), Hospital Universitario "Dr. José E. González", Collage of Medicine, Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo Leon 64460, Mexico.

Margarita L Martinez-Fierro (ML)

Molecular Medicine Laboratory, Human Medicine and HS Academic Unit, Universidad Autonoma de Zacatecas, Zacatecas, Zacatecas 98160, Mexico.

Iván Delgado-Enciso (I)

Faculty of Medicine, Universidad de Colima, Colima, Colima 28040, Mexico.
Colima State Cancer Institute, Universidad de Colima, Colima, Colima 28040, Mexico.

Mayra Alejandra Gomez-Govea (MA)

Laboratory of Molecular and Structural Physiology, Collage of Biological Sciences, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon 66451, Mexico.

Laura Elia Martínez-de-Villarreal (LE)

Department of Genetics, Collage of Medicina, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 64460, Mexico.

Diana Reséndez-Pérez (D)

Laboratory of Immunology and Virology, Collage of Biological Sciences, Universidad Autónoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon 66451, Mexico.

Iram Pablo Rodríguez-Sánchez (IP)

Colima State Cancer Institute, Universidad de Colima, Colima, Colima 28040, Mexico.

Classifications MeSH